Botulinum toxin in pain management of soft tissue syndromes

Clinical Journal of Pain

Volumn 18, Issue 6 SUPPL., 2002, Pages

  Smith, Howard S ^a   Audette, Joseph ^b   Royal, Mike A ^c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c ELAN PHARMACEUTICALS   (United States)

Author keywords

Botulinum toxin; Dystonia; Fibromyalgia; Soft tissue syndromes

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; LIDOCAINE; LOCAL ANESTHETIC AGENT; METHYLPREDNISOLONE; STEROID;

ANALGESIA; ANALGESIC ACTIVITY; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DYSPHAGIA; ELECTROSTIMULATION; FEMALE; FIBROMYALGIA; FLU LIKE SYNDROME; HUMAN; INJECTION PAIN; ISCHIALGIA; MALE; MUSCLE CONTRACTION; MUSCLE EXCITATION; MUSCLE SPASM; MUSCLE WEAKNESS; NERVE CELL PLASTICITY; NEUROPATHIC PAIN; NONHUMAN; OUTCOMES RESEARCH; PAIN; PAIN ASSESSMENT; PATHOGENESIS; PATIENT SELECTION; PHYSIOTHERAPY; PRIORITY JOURNAL; REVIEW; SOFT TISSUE DISEASE; TREATMENT INDICATION; TREATMENT PLANNING; XEROSTOMIA;

BOTULINUM TOXINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROMYALGIA; HUMANS; INJECTIONS, INTRAMUSCULAR; MYOFASCIAL PAIN SYNDROMES; PAIN;

EID: 0036841632     PISSN: 07498047     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002508-200211001-00006     Document Type: Review

References (83)

1. Raj PP. Botulinum toxin in the treatment of pain associated with musculoskeletal hyperactivity. Curr Rev Pain 1997;1:403-16.
2. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991;324:1186-94.
3. Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology 1990;40:277-80.
4. Ludlow CL, Naunton RF, Sedory SE, et al. Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia. Neurology 1988;38:1220-5.
5. Soulayrol S, et al. Local botulinum toxin injection therapy in neurology. Presse Med 1993;22:957-63.
6. Borodic GE, Acquadro MA. The use of botulinum toxin for the treatment of chronic facial pain. J Pain 2002;3:21-7.
7. Relja M. Botulinum toxin Type A in the treatment of tension-type headache. Presented at the 9th World Congress on Pain, Vienna, Austria, August 22-27, 1999, and at the International Conference 1999: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins, Orlando, FL, November 16-18, 1999.
8. Binder WJ, Brin MF, Blither A, et al. Botulinum toxin type A (Botox) for treatment of migraine. Semin Cutan Med Surg 2001; 20:93-100.
9. Childers MK, Wison DJ, Galate JF, et al. Treatment of painful muscle syndromes with botulinum toxin: A review. J Back Musculoskel Rehab 1998;10:89-96.
10. Travell JG. Referred pain from skeletal muscle. NY State J Med 1952;55:331-9.
11. Borg-Stein J, Simons DG. Myofascial pain. Arch Phys Med Rehab 2002;83(suppl 1):S40-9.
12. Travell JG, Simons DG. Myofascial Pain and Dysfunction: The Trigger Point Manual. Vol. 1. Baltimore: Williams & Wilkins, 1983.
13. Simons DG, Caperan A, Penot-Ragon C, et al. Referred phenomena of myofascial trigger points. In: Vechiet L, Albe-Fessard D, Lindblom U, eds. New Trends in Referred Pain and Hyperalgesia. Amsterdam: Elsevier, 1993:341-57.
14. Tunks E, McCain GA, Hart LE, et al. The reliability of examination for tenderness in patients with myofascial pain, chronic fibromyalgia and controls. J Rheumatol 1995;22:944-52.
15. Gerwin RD, Shannon S, Hong C-Z. Identification of myofascial trigger points: Interrater agreement and effect of training. J Musculoskel Pain 1995;3(suppl 1):55.
16. Audette J, Wang F, Smith H. The electrophysiological characteristics of myofascial pain: Characteristics of the local twitch response in subjects with active myofascial pain of the neck compared to a control group with latent trigger points. NEPA J 2002;7:10-4.
17. Fricton JR, Auvinen MD, Dykstra D, et al. Myofascial pain syndrome: Electromyographic changes associated with local twitch response. Arch Phys Med Rehab 1985;66:314-7.
18. Harden RN, Bruehl SP, Fass S, et al. Signs and symptoms of the myofascial pain syndrome: A national survey of pain management providers. Clin J Pain 2000;16:64-72.
19. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72.
20. Wolfe F, Simons DG, Fricton J, et al. The fibromyalgia and myofascial pain syndromes: Preliminary study of tender points and trigger points in persons with fibromyalgia, myofascial pain syndrome and no disease. J Rheumatol 1992;19:944-51.
21. Lalli F, Gallai V, Tambasco N, et al. Botulinum A toxin versus lidocaine in the treatment of myofascial pain: A double-blind randomized study. Presented at the International Conference 1999: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins, Orlando, FL, November 16-18, 1999.
22. Porta M. A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain 2000;85:101-5.
23. Acquadro MA, Borodic GE. Treatment of myofascial pain with botulinum A toxin. Anesthesiology 1994;80:705-6 (Letter).
24. Alo KM, Yland MJ, Kramer DL, et al. Botulinum toxin in the treatment of myofascial pain. Pain Clin 1997;10:107-16.
25. Grana EA. Treatment of chronic cervical myofascial pain with botulinum toxin. Arch Phys Med Rehab 1998;79:1172.
26. Royal MA, Gordin V, Huebert JD, et al. Botulinum toxin Type A (Botox®) in the treatment of refractory myofascial pain. Abstract presented at the International Conference 1999: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins. Orlando, FL, November 16-18, 1999, 73.
27. Nalamachu S. Treatment with botulinum toxin type B (Myobloc™) injections in three patients with myofascial pain. Abstract presented at the AAPM 18th Annual Meeting, San Francisco, CA, February 26-March 3, 2002.
28. Smith H, Audette J, Dey R, et al. Botulinum toxin type B for a patient with myofascial pain. Abstract presented at the AAPM 18th annual meeting. San Francisco, CA, February 26-March 3, 2002.
29. Dubin A, Smith H, Tang J. Evaluation of botulinum toxin type B (Myobloc™) injections in a patient with painful muscle spasms. Pain 2002;3(suppl 1):11 (abstract).
30. Porta M, Perretti A, Gamba M, Luccarelli G, Fornari M. The rationale and results of treating muscle spasm and myofascial syndromes with botulinum toxin type A. Pain Digest 1998;8:346-52.
31. Wheeler AH, Goolkasian P, Gretz SS. A randomized, doubleblind, prospective pilot study of botulinum toxin injection for refractory, unilateral cervicothoracic, paraspinal, myofascial pain syndrome. Spine 1998;23:1662-7.
32. Knusel B, DeGryse R, Grant M, et al. Intramuscular injection of botulinum toxin type A (BOTOX) in chronic low back pain associated with muscle spasm. Data presented at 17th Annual Scientific Meeting, American Pain Society, Nov 5-8, 1998, San Diego, CA.
33. Freund BJ, Schwartz M. Treatment of whiplash-associated neck pain with botulinum toxin A: A pilot study. Headache 2000;40:231-6 and J Rheum 2000;27:481-4.
34. Freund BJ, Schwartz M. Treatment of whiplash-associated neck pain with botulinum toxin A: A pilot study. Headache 2000;40:231-6 and J Rheum 2000;27:481-4.
35. Opida CL. Evaluation of Myohloc™ (botulinum toxin type B) in patients with post-whiplash headaches. Abstract presented at the AAPM 18th Annual Meeting, San Francisco, CA, February 26-March 3, 2002.
36. Taqi D, Gunyea I, Bhakta B, et al. Botulinum toxin Type A (Botox®) in the treatment of refractory cervicothoracic myofascial pain. Pain 2002;3(suppl 1):16 (abstract).
37. Taqi D, Royal M, Gunyea I, et al. Botulinum toxin type B (Myobloc™) in the treatment of refractory myofascial pain. Pain 2002:3(suppl 1):16 (abstract).
38. Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: A randomized double blind study. Neurology 2001;56:1290-3.
39. Indahl A, Holm S. Chronic low back pain and muscle involvement. Abstract presented at EFIC 2000, Nice, France, September 26-29, 2000.
40. Fannucci E, Masala S, Sodani G, et al. CT-guided injection of botulinic toxin for percutaneous therapy of piriformis muscle syndrome with preliminary MR1 results about denervation process. Eur Radiol 2001;11:2543-8.
41. Fishman LM. Myohloc in the treatment of piriformis syndrome - A dose finding study. Abstract presented at the AAPM 18th Annual Meeting, San Francisco, CA, February 26-March 3, 2002.
42. Brin MF, Fahn S, Moskowitz C, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 1997;12:722-6.
43. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999;53:1439-6.
44. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999;53:1431-8.
45. Fillippi GM, Errico P, Santarelli R, et al. Botulinum toxin effects on rat jaw muscle spindles. Acta Otolaryngol (Stockh) 1993;113:400-4.
46. Giladi N. The mechanism of action of botulinum toxin Type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site. J Neurol Sci 1997;152:132-5.
47. Borodic GE, Acquadro M, Johnson EA. Botulinum toxin therapy for pain and inflammatory disorders: Mechanisms and therapeutic effects. Exp Opin Invest Drugs 2001;10:1531-44.
48. Woolf CJ, Shortland P, Raynolds MJ, et al. Reorganization of central terminals of myelinated primary afferents in the rat dorsal horn following peripheral axotomy. Comp Neurol 1995:360:12134.
49. McLachlan EM, Janig W, Devor M, et al. Peripheral nerve injury triggers noradrenergic sprouting in tie dorsal root ganglion. Nature 1993:363:53-6.
50. Rand MJ, Whaler BC. Impairment of sympathetic transmission by botulinum toxins. Nature 1965;206:588.
51. Sanchez-Prieto J, Sihra TS, Evans D, et al. Botlinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes. Eur J Biochem 1987;165:675-81.
52. Mills CD, Johnson KM, Hulsebosch CE. Group I metabotropic glutamate receptors in spinal cord injury: Roles in neuroprotection and the development of chronic central pain. J Neurotrauma 2002; 19:23-42.
53. Alfredson H, Lorentzon R. Chronic tendon pain: No signs of inflammation but high concentrations of glutamate. Curr Drug Targets 2002;3:43-54.
54. Harrington J, Messier A, Bereiter D, et al. Herniated lumbar disc materials as a source of free glutamate available to affect pain signals through the dorsal root ganglion. Spine 2000;25:929-36.
55. Wiegand H, Wellhoner HH. The action of botulinum A neurotoxin on the inhibition by antidromic stimulation of the lumbar monosynaptic reflex. Naunym Schmiedebergs Arch Pharmacol 1977; 298:235-8.
56. Aoki R. The development of BOTOX® - Its history and pharmacology. Pain Digest 1998;8:337-41.
57. Hohne-Zell B, Galler A, Schepp W, et al. Functional importance of synaptobrevin and SNAP-25 during exocytosis of histamine by rat gastric enterochromaffin-like cells. Endocrinology 1997;138:5518-26.
58. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000;38:245-58.
59. Ishikawa H, Mitsui Y, Yoshitomi T, et al. Presynaptic effects of botulinum toxin Type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthahnol 2000;44:106-9.
60. Geerlings A, Nunez E, Lopez-Corcuera B, et al. Calcium- and syntaxin 1-mediated trafficking of the neuronal glycine transporter GLYT2. J Biol Chem 2001;276:17584-90.
61. Ibrahim M, Frank E. Botulinum toxin type B (Myobloc) for axial component of neuropathic pain: A case report. Pain 2002;3(suppl 1):18(abstract).
62. Kamen L. Botulinum toxin type B (Myobloc) in the treatment of neuromuscular pain associated with brachial plexopathy. Pain 2002;3(suppl 1):12 (abstract).
63. Aoki KR, Cui M. Botulinum toxin type A: Potential mechanism of actions in pain relief. Presented at 37th Annual Meeting of the Interagency Botulism Research Coordinating Committee, Asilomar, CA, October 17-20, 2000.
64. Kim HJ, Seo KI, Yoon SM. Effects of the Type A botulinum toxin on the superior cervical ganglia in rabbits. Soc Neurosci Abstr 2001;27:1947 (abstract).
65. Cui M, Li Z, You S, et al. Mechanisms of the antinociceptive effect of subcutaneous Botox® inhibition of peripheral and central nociceptive processing. Poster presented at the International Conference 2002: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins. Hannover, Germany, June 8-11, 2002.
66. Jabbari B, Maher C. Botulinum toxin A relieved the central, burning pain of spinal cord origin. Poster presented at the International Conference 2002: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins. Hannover, Germany, June 8-11, 2002.
67. Lang AM. A pilot study of botulinum toxin Type A (BOTOX®), administered using a novel injection technique, for the treatment of myofascial pain. Am J Pain Mgt 2000:10:108-12.
68. O'Brien C. Discussion: Optimal doses for treatment with botulinum toxins. In: Lees A. ed. Optimal patient management with botulinum toxins. evidence and experience. Round Table Series 74. London: Royal Society of Medicine Press, 2000:64-76.
69. WEMOVE™ (Worldwide Education and Awareness for Movement Disorders; wemove.org; 800-437-6682): Practical considerations for the clinical use of botulinum toxin type B: A self-study continuing medical education activity. Consensus Guidelines on Myobloc Dosing and Dose Modifiers. February 2002:16-21.
70. Dressler R, Benecke R. Type B botulinum toxin: Opportunities and limitation of clinical application. Klin Nearophysiol 2001;32:240-3.
71. Comella CL, Tanner CM, DeFoor-Hill L, et al. Dysphagia after botulinum toxin injections for spasmodic torticollis. Neurology 1992;42:1307-10.
72. Comella CL, Jankovic J, Brin MF. Use of botulinum toxin type A in the treatment of cervical dystonia. Neurology 2000;55(12 suppl 5):S15-21.
73. Lange DJ, Brin MF, Warner CL, et al. Distant effects of local infection of botulinum toxin. Muscle Nerv 1987;10:552-5.
74. LeWitt PA, Trosch RM. Idiosyncratic adverse reactions to intramuscular botulinum toxin type A injection. Mov Disord 1997;12:1064-7.
75. Ansved T, Odergren T, Borg K. Muscle fiber atrophy in leg muscles after botulinum toxin type A treatment of cervical dystonia. Neurology 1997;48:1440-66.
76. Lange DJ, Brin MF, Fahn S, et al. Distant effects of locally injected botulinum toxin: Incidence and course. In: Fahn S, Marsden CD, Calne DB, eds. Advances in Neurology 50: Dystonia 2; Raven Press. New York, 1988:609-13.
77. Claus D, Druschky A, Erbguth F. Botulinum toxin: Influence on respiratory heart rate variation. Mov Disord 1995;10:574-9.
78. Matarasso SL, Complications of botulinum A exotoxin for hyperfunctional lines. Dermatol Surg 1998;24:1249-54.
79. Garner CG, Straube A, Witt TN, et al. Time course of distant effects of local injections of botulinum toxin. Mov Disord 1993;8:33-7.
80. Borodic G. Myasthenic crisis after botulinum toxin. Lancet 1998;352:1832.
81. Erbguth F, Claus D, Englehardt A, et al. Systemic effect of local botulinum toxin injections unmasks subclinical Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1993;56:1235-6.
82. Fiacchino F, Grandi L, Soliveri P, et al. Sensitivity to vecuronium after botulinum toxin administration. J Neurosurg Anesth 1997;9:149-55.
83. Settler P, Burke D, Callaway J, et al. Stability of Myobloc™ (botulinum toxin type B) in preserved saline. Poster presented at the International Conference 2002: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins. Hannover, Germany, June 8-11, 2002.